Delivery Order HHSF223201510001I-HHSF22301005T
- This is a $897,471 firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. LBERI, a non-profit contract research organization, will provide preclinical research services to support the...
- This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
- This is a firm fixed-price delivery order issued by the Department of Health and Human Services Food and Drug Administration under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract. The $1,408,956.00 task order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to perform detection and characterization of DNA adducts generated by tobacco flavorants in aerosol...
- This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to conduct in vitro evaluation of the toxic profiles of tobacco additives in a systematic tiered approach. The contract has a ceiling value of $1,552,162.00 and an ultimate completion date of July 14, 2018. It was issued under the FDA's "In Vivo Toxicology of Tobacco...
- This is a firm-fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The $1,405,301.00 contract is for in vitro evaluation of the toxic profiles of tobacco additives using a systematic tiered approach. It is part of the larger "In Vivo Toxicology of Tobacco 2015-2020" indefinite delivery, indefinite quantity (IDIQ) contract vehicle....
- This is a delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit organization, for a project titled "CYTOTOXICITY OF COMMON SOLVENTS USED IN LIQUID NICOTINE FORMULATIONS". The contract has a potential value of $1,149,919.00 and a completion date of April 15, 2021. This delivery order is part of a larger indefinite delivery/indefinite quantity...
- This firm fixed-price delivery order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $2,472,244.00 contract is for the evaluation of e-cigarette aerosol in in vivo nonclinical models and was issued under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery, indefinite quantity (IDIQ) contract. Lovelace Biomedical Research Institute has...
- This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. LBERI, a non-profit contract research organization,...
- This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for $679,680.00. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Under this task order, LBERI will conduct an assessment of tobacco products and tobacco product constituents' genetic toxicology using in vitro assays to compare the...
- This is a sole source, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization located in Albuquerque, New Mexico. The 24-month contract, valued at $7,058,881.75, is for the completion of toxicological studies for the FDA's Center for Tobacco Products. The award is not set aside for any small business category. Lovelace Biomedical Research Institute has significant experience...
- In Vivo Toxicology of Tobacco 2015-2020Master IDIQ
- HHSF223201510001IIndefinite Delivery Contract
- HHSF223201510001I-HHSF22301005TDelivery Order
This firm-fixed-price delivery order was issued under the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The $1,412,105.00 contract was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute, a non-profit contract research organization. The contract is for the "Assessment of Genotoxic Potential of Serially Diluted Whole Tobacco Smoke Using Ames Micronucleus and PIG-A Assays". There was no set-aside designation for this award. LBERI has expertise in areas such as inhalation toxicology, infectious disease modeling, and translational science, and conducts research on behalf of federal agencies including NIH, NIAID, NCATS, and BARDA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Supplemental Agreement for work within scope | $0 | 12/31/19 | |
| 2 | Change Order | $0 | 11/20/18 | |
| 1 | Other Administrative Action | $0 | 11/7/17 | |
| Not listed | Not listed | $1.4m | 9/8/17 |